SPOTLIGHT -
Advancing the Perioperative Management of Bladder Cancer
Following the important information provided by the phase 3 VESPER trial, Jean Hoffman-Censits, Md said there are several noteworthy ongoing phase 3 neoadjuvant immunotherapy studies in bladder cancer.
Recurrence Detection Rates Appear Favorable With Novel PSMA Imaging Agent in Prostate Cancer
Utilizing 18F-rhPSMA-7.3 imaging, detection rates for prostate cancer recurrence were favorable in the phase 3 SPOTLIGHT study.
